Surgical Sequencing in Esophageal Cancer
-
By
February 5, 2026
-
3 min
-
1
The study compared neoadjuvant chemoradiotherapy and surgery with adjuvant therapy.
-
2
No significant overall survival difference was found.
-
3
Complete pathologic response greatly improved outcomes.
-
4
Similar adverse effect rates were observed between groups.
-
5
Tumor resection with negative margins was achieved in over 95% of patients.
-
6
Study limitations include single-center design and modest sample size.
-
7
Tailored treatment strategies are essential for optimal patient outcomes.
-
A phase 3 clinical trial from Sichuan Cancer Hospital investigated treatment outcomes for locally advanced esophageal squamous cell carcinoma. Patients underwent either neoadjuvant chemoradiotherapy before surgery or surgery followed by adjuvant therapy. With a median follow-up of five years, both approaches showed similar overall and disease-free survival rates. Notably, patients achieving a pathologic complete response after neoadjuvant treatment had significantly better long-term outcomes, indicating a need for tailored treatment strategies based on individual responses.
-
1
The study compared neoadjuvant chemoradiotherapy and surgery with adjuvant therapy.
-
2
No significant overall survival difference was found.
-
3
Complete pathologic response greatly improved outcomes.
-
4
Similar adverse effect rates were observed between groups.
-
5
Tumor resection with negative margins was achieved in over 95% of patients.
-
6
Study limitations include single-center design and modest sample size.
-
7
Tailored treatment strategies are essential for optimal patient outcomes.
Listen Tab content
